Clinical Trial: A Prospective, Single-Center, Phase Ib Clinical Trial of IBI363 Combined with Bevacizumab in Patients with Unresectable or Metastatic Renal Cell Carcinoma Progressing After Prior Immunotherapy (China)

China, Nov. 3 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Single-Center, Phase Ib Clinical Trial of IBI363 Combined with Bevacizumab in Patients with Unresectable or Metastatic Renal Cell Carcinoma Progressing After Prior Immunotherapy'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135754

Registration Time: 2026/11/02

Type: Interventional study

Primary Sponsor: West China Hospital of Sichuan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=307263

Published by HT Digital Content Services with permission from Health Daily Digest....